PM Modi's government has in recent months slashed prices of medical devices such as knee implants and heart stents by up to 75 percent to m...

The Department of Pharmaceuticals has directed stent importers and domestic manufacturers to maintain their production, import and supply f...

The move may affect multinational cos that have been trying to withdraw their high-end stents from India after the drug pricing watchdog ca...

Five months after it was blocked from discontinuing its brands 'Promus Premier' & 'Synergy' in India, Boston Scientific has approached NPPA...

This year, domestic stent firms are aiming for 60 per cent of the market estimated to be Rs 1,200 crore now due to a drop in the average pr...

The government is expected to hold discussions to decide on these requests only in February, a year after it first capped prices of these l...

Abbott publicly announced intentions to stop global sales of dissolvable scaffold ‘Absorb’, which has been mired in controversy for risks r...

NPPA Chairman Bhupendra Singh said the essential medicines list - comprised of more than 350 items, most of them drugs should include ballo...

The move comes in the wake of various multinationals, including Abbott and Medtronic, seeking permission to withdraw some of their products...

It's not clear if firms can withdraw their products as the Department of Pharmaceuticals had recently prevented stent makers from taking th...

Addition of stents to essential list contrary to international norms, says US embassy official.

The National Pharmaceutical Pricing Authority (NPPA) met stent makers and importers today to discuss issues like pricing and availability o...

Indian stents are not drastically cheaper to imported stents, says the Medical Technology Association of India

Given the unmet medical need in India, there are "grand possibilities" for greater FDI into India in the medical device sector, USIBC said ...

Both deals are fairly unique according to industry trackers, who said that these segments have not attracted sizeable capital due to factor...

The decision of Johnson&Johnson to stop making its popular drug eluting stent has opened up new opportunities for competitors Abbott & Bost...

US regulators may recommend stricter testing standards for cardiac stents to ensure that the devices are safer than those now available, ac...